Ovarian Cancer Claim For Antisoma Oncologic On Back Burner
This article was originally published in The Pink Sheet Daily
Executive Summary
Disappointing Phase II results for ASA404, which is licensed to Novartis, will not impact research in lung, prostate cancer.